Abstract
There is little debate over the essential role of IgE in allergic reactions. During an allergic response, CD4+ T lymphocytes of the Th2 phenotype stimulate allergen-specific B cells to produce IgE molecules via the release of IL-4/IL-13. The receptors for IgE are found on a multitude of different cells and two different types have been identified: the high-affinity receptor (FcεRI) on mast cells, basophils, and antigen-presenting cells, and the low-affinity receptor (FcεRII or CD23) on B lymphocytes, monocytes/macrophages, eosinophils, dendritic cells, and epithelial cells. After interaction with allergens, IgE-armed cells release a number of inflammatory mediators and enhance and redirect antigen presentation. This cascade of events seems to have a crucial role in the generation and persistence of symptoms in allergic diseases. The development of drugs that interfere with IgE production and function may therefore represent a more specific approach to treat these pathological conditions [1, 2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Heusser C, Jardieu P (1998) Therapeutic potential of anti-IgE antibodies. Curr Opin Immunol 9: 805–814
Jardieu P (1995) Anti-IgE therapy. Curr Opin Immunol 7: 779–782
Shimoda K, van Deuren J, Sangster MY, Sarawar SR, Carson RT, Tripp RA, Chu C, Quelle FW, Nosaka T, Vignali DA et al (1996) Lack of IL-4 induced Th2 responses and IgE class switching in mice with disrupted Stat 6 gene. Nature 380: 630–633
Paul WE (1997) fnterleukin 4: signalling mechanisms and control of T cell differentiation. Ciba Foundation Symposium 204: 208–216
Flores-Romo L, Shields J, Hubert Y, Graber P, Aubry J-P, Gauchat J-F, Ayala G, Allet B, Gnavaz M, Bazin H et al (1993) Inhibition of an in vivo antigen-specific IgE response by antibodies to CD23. Science 261: 1036–1041
Manning DD, Nanning JK, Reed NR (1976) Suppression of reaginic antibody (IgE) formation in mice by treatment with anti-μ antiserum. J Exp Med 144: 288–292
Bozelka BE, McCants ML, Salvaggio JE, Lehrer SB (1992) IgE isotype suppression in anti-μ treated mice. Immunology 46: 527–532
Bozelka BE, McCants ML, Salvaggio JE, Lehrer SB (1885) Effect of anti-IgE on total and specific IgE levels in adult mice. Int Arch Allergy Appl Immunol 78: 51–56
Hook WA, Berenstein E, Basciano LA, Fox PC, Siraganian RP (1981) Monoclonal antibodies to human IgE. Fed Proc 40: 986 A 41777
Banyash M, Eshar Z (1984) Inhibition of IgE binding to mast cells and basophils by monoclonal antibodies to murine IgE. Eur J Immunol 14: 799–807
Chang TW, Davis FM, Sun NC, Sun CRY, MacGlashan DW, Hamilton RG (1990) Monoclonal antibodies specific for human IgE-producing B cells: a potential therapeutic for IgE-mediated allergic diseases. Bio/Technology 8: 122–126
Heusser CH, Bews J, Brinkmann V, Delespesse G, Kilchnerr E, Ledermann F, LeGros G, Wagner K (1991) New concept of IgE regulation. Int Archs Allergy Appl Immunol 94: 87–90
Banyash M, Kerhy M, Eshar Z (1988) Anti-IgE monoclonal antibodies directed at the Fcε receptor binding site. Mol Immunol 25: 705–711
Davis FM, Gossett LA, Pinkston KL, Liou RS, Sun LK, Kim YW, Chang NT, Chang TW, Wagner K, Bews J et al (1993) Can anti-IgE be used to treat allergy? Springer Seminars in Immunopathology 15: 51–73
Presta L, Shields R, O’Connels L, Lahr S, Porter J, Gorman C, Jardieu P (1994) The binding site of on human Immunoglobulin E for its high affinity receptors. J Biol Chem 269(42): 26368–26373
Nissim A, Eshar Z (1991) Localization of the Fcε receptor binding site to the third constant domain of IgE. Int Arch Allergy Appl Immunol 94: 93–95
Weetal M, Shopes B, Holowka D, Baird B (1990) Mapping the site of interaction between murine IgE and its high affinity receptor with chimeric Ig. J Immunol 145(11): 3849–3854
Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF (1988) Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response. J Natl Cancer Inst 80: 937–947
Jaffers GJ, Fuller TC, Cosimi AB, Russel PS, Winn HJ, Colvin RB (1986) Monoclonal antibody therapy: anti-idiotypic and non-anti-idiotypic antibodies to OKT3 arising despite intense immunosuppression. Transplantation 41: 572–578
Shawler DL, Bartholomew RM, Smith LM, Dillman RO (1985) Human immune response to multiple injection of murine monoclonal IgG. J Immunol 135: 1530–1535
Sears HF, Herlyn D, Steplewski Z, Koprowski H (1984) Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma. J Biol Response Mod 3: 138–150
Miller RA, Oseroff AR, Stratte PT, Levy R (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62: 988–995
Kolbinger F, Saldanha J, Hardman N, Mendig MM (1993) Humanization of a mouse anti-human IgE antibody: a potential therapeutic for IgE-mediated allergies. Protein Engineering 6(8): 971–980
Presta L, Lahr S, Shields R, Porter J, Gorman C, Fendly B, Jardieu P (1993) Humanization of an antibody directed against Immunoglobulin E. J Immunol 151(5): 2623–2632
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT (1984) Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci USA 81: 6851–6855
Reichmann L, Clark M, Waldmann H, Winter G (1988) Reshaping human antibodies for therapy. Nature 332: 323–327
Jones PT, Dear PH, Foote J, Neuberger MS, Winter G (1986) Replacing the complementarity-determining regions in human antibody with those from a mouse. Nature 321: 522–525
Amit AG, Mariuzza RA, Phillips SEV, Poljak RJ (1986) Three-dimensional structure of an antigen-antibody complex at 2.8 A resolution. Science 233:747–753
Carter P, Presta L, Gorman CM, Ridgway JBB, Henner D, Wong WLT, Rowland AM, Kotts C, Carver ME, Shepard MH (1992) Humanization of an anti-p185 HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89: 4285–4289
Corne J, Djukanovic R, Thomas L, Warner J, Botta L, Grandordy B, Gygax D, Huesser C, Patalano F, Richardson W et al (1997) The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: Efficacy, safety and pharmacokinetics. J Clin Invest 99(5): 879–887
Togias A, Corren J, Shapiro G, Reimann JD, von Schlegell A, Wighton TG, Adelmann DC (1998) Anti-IgE treatment reduces Skin Test (ST) reactivity. J Allergy Clin Immunol 101 (1 pr2): s171 Abstract 706
Racine-Poon A, Botta L, Chang TW, Davis FM, Gygax D, Liou RS, Rohane P, Stahelin T, Van Steijn A, Frank W (1997) Efficacy, pharmacodynamics and pharamacokinetics of CGP 51901, an anti-immunoglobulin E chimeric monoclonal antibody, in patients with seasonal allergic rhinitis. Clin Pharmacol Ther 62: 675–690
Casale TB, Bernstein IL, Busse WW, LaForce CF, Tinkelman DG, Stoltz RR, Dockhorn RJ, Reimann JR, Su JQ, Fick RB, Adelman DC (1997) Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. J Allergy Clin Immunol 100: 110–121
Cockcroft DW, Murdock KY (1987) Comparative effects of inhaled salbutamol, sodium cromoglycate and bechlomethasone dipropionate on allergen-induced early asthmatic responses, late asthmatic responses, and bronchial responsiveness to histamine. J Allergy Clin Immunol 79: 734–740
Cockcroft DW, Swystun VA, Baghat R (1995) Interaction of inhaled β2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 152: 1485–1489
Holgate ST, Robinson C, Church MK (1993) Mediators of immediate hypersensitivity. In: E Middleton Jr, CE Reed, EF Regis, NF Adkinson Jr, JW Yuninger, Busse WW (eds): Allergy principle and practice. 4th ed, Mosby, St Louis, 267–301
Zweiman B (1993) The late phase response: role of IgE, its receptor, and cytokines. Cur Opin Immunol 5: 950–955
Boulet L-P, Chapman KR, Coté J, Kaira S, Bhagat R, Swystun VA, Laviolette M, Cleland LD, Deschesnes F, Su JQ et al (1997) Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. Am J Respir Crit Care Med 155: 1835–1840
Cockcroft DW, Swystun VA, Bhagat R (1995) Interaction of β2 agonist and inhaled corticosteroid on airway responsiveness to allergen and methacholine. Am J Respir Crit Care Med 152: 1485–1489
Fahy JV, Flemming HE, Wong HH, Liu JT, Su JQ, Reimann J, Fick RB, Jr, Boushey HA (1997) The effect of an anti-IgE monoclonal antibody on the early-and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155: 1828–1834
Burrows B, Martinez FD, Holonen M, Barbee RA, Cline MG (1989) Association of asthma with serum IgE levels and skin test reactivity to allergens. N Engl J Med 320: 271–277
Sears MR, Burrows B, Flannery EM, Herbison GB, Hewitt CJ, Holdaway MD. (1991) Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children. N Engl J Med 325: 1067–1071
Sunyer J, Munoz A and the Spanish Group of the European Asthma Study (1996) Concentration of methacholine for bronchial responsiveness according to symptoms, smoking and immunoglobulin E in a population based study in Spain. Am J Respir Crit Care Med 153: 1273–1279
Pollart S, Chapman M, Fiocco G, Rose G, Platt-Mills A (1989) Epidemiology of acute asthma: IgE antibodies to common inhalant allergens as a risk factor for emergency room visits. J Allergy Clin Immunol 83: 875–882
Fick RB, Simon SJ, Su JQ, Zeiger R and the E25 Study Group (1998) Anti-IgE (rhuM-Ab) treatment of the symptoms of moderate to severe allergic asthma. Ann Asthma Allergy Immunol 80(1): 80 Abstract 8
Metzger WJ, Fick RB and the E25 Asthma Study Group (1998) Corticosteroid (CS) withdrawal in a study of recombinant humanized monoclonal antibody to IgE (RhuM-Ab E25). J Allergy Clin Immunol 101 (1 pt 2): s231 Abstract 960
MacGlashan DW, Jr, Bochner B, Adelman D, Jardieu P, Togias A, McKenzie-White J, Sterbinsky SA, Hamilton R, Lichtenstein LM (1997) Down-regulation of FcεRI expression on human basophils during anti-IgE antibody therapy. J Immunol 158: 1438–1445
Saini S, MacGlashan DW, Jr, Adelman D, Togias A, Lichtenstein LM, Blochner BS (1998) Discontinuation of anti-IgE infusions restores basophils (BASO) IgE and FcεRIα expression, and IgE-dependent histamine release. J Allergy Clin Immunol 101 (1 pt 2): s105 Abstract 437
Capron A, Dessaint JP, Haque A, Capron M (1982) Antibody-dependent cell-mediated cytotoxic against parasites. Progr Allergy 31: 234–267
Rihet P, Demuere C, Bourgois A, Prata A, Dessein A (1991). Evidence for an association between human resistance to Schistosoma mansoni and high-larval IgE levels. Eur J Immunol 21: 2679–2686
Hagan P, Blumenthal UJ, Dunn D, Simpson AJG, Wilkins HA (1991) Human IgE, IgG4 and resistance to reinfection with Schistosoma haematohium. Nature 349: 243–245
Welge-Roussel F, Ariault C, Damonneville M, Capron A. (1991) Functional analysis of a T cell line specific for antiidiotypic antibodies to a Schistosoma mansoni protective epitope. II. Induction of protective immunity in experimental rat schistosomiasis. J Immunol 147: 3967–3972
Watanabe N, Katakura K, Kobayashi A, Okumura K, Ovary Z (1989) Protective immunity and eosinophilia in IgE-deficient SJA/9 mice infected with Nippostrogylus brasiliensis and Trichinella spiralis. Proc Natl Acad Sci USA 85: 4460–4462
Amiri P, Haak-Frendscho M, Robbins K, McKerrow J, Stewart T, Jardieu P. (1994) Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni infected normal and IFNγ knockout mice. J Exp Med 180: 43–51
Fisherman E (1960) Does the allergic diathesis influence malignancy? Allergy 31: 74–78
Allegra J, Lipton A, Harvey H, Luderer J, Brenner D, Mortel R, Semers L, Gillin M, White D, Trautlein J (1976) Decreased prevalence of immediate hypersensitivity (atopy) in a cancer population. Cancer Res 36: 3225–3226
McKee W, Arnold CA, Perlman M (1967) A double blind study of the comparative incidence of malignancy and allergy. J Allergy Clin Immunol 39: 294–301
Shapiro S, Heinonen O, Siskind V (1971) Cancer and allergy. Cancer 29: 386
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer Basel AG
About this chapter
Cite this chapter
Patalano, F. (1999). Anti-IgE Agents. In: Sampson, A.P., Church, M.K. (eds) Anti-Inflammatory Drugs in Asthma. Progress in Inflammation Research. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8751-9_8
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8751-9_8
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9757-0
Online ISBN: 978-3-0348-8751-9
eBook Packages: Springer Book Archive